BREAKING NEWS
ASU Biodesign Institute: A new model of Alzheimer’s progression
Alzheimer’s disease is the most common form of dementia and is characterized by neurodegeneration in regions of the brain involved in memory and learning. Amyloid beta and tau are two toxic proteins that build up in disease and cause...
Read more
Arizona Researchers Receive $27.5 Million NIH Grant to Study People at Six Levels of Genetic Risk for Alzheimer’s Disease
The new study will inform the discovery of disease mechanisms and help find effective prevention therapies Banner Alzheimer’s Institute (BAI) has received a grant expected to total $27.5 million over five years from the National Institute on Aging...
Read more
Jeffrey Kordower to lead Arizona’s collaborative fight against Neurodegenerative Diseases
The ASU – Banner Neurodegenerative Disease Research Center, a partnership between Banner Health and Arizona State University, has named Jeffrey Kordower, PhD, as its founding director to lead the aggressive pursuit of new battleground tactics in the war against Alzheimer’s...
Read moreNational Institute for Health + Duke University – Alzheimer’s Association Workshop (online), March 9-10, 2021
Register online today for NIA-Duke-Alzheimer’s Association Workshop on March 9-10, 2021. The workshop is dedicated to improving the understanding of how existing analytic methods and available population data (such as Medicare) can be leveraged to make progress in understanding...
Read more
National Institute on Aging Program Accepting Applications for Early Investigators Interested in Health Disparity Research
The 2021 Butler-Williams Scholars Program is now accepting applications through March 31, 2021. The program will be convened virtually August 24-26, 2021 and will feature presentations from investigators conducting timely research across all phases of science. The Scholars will have...
Read moreF.D.A. Panel Declines to Endorse Alzheimer’s Drug – The New York Times
The drug, aducanumab, made by Biogen, would be the first new Alzheimer’s treatment in nearly two decades. But the advisory panel said there was not enough evidence of its effectiveness in slowing cognitive decline. Click Here to Read the...
Read more